Facioscapulohumeral muscular dystrophy (FSHD or FSH) is characterised by muscle weakness that affects the muscles of the face, shoulders and arms and appears in adolescence or adulthood. This disease is due to a change in the structure of a small region of chromosome 4, the D4Z4 region.
Clinical trials ongoing at the Institute:
- Resolve-RD France = Resolve Expansion: CTRN FSHD France – Prospective 18 months MRI Study
- PROGRESS FSHD: Remote assessment and artificial intelligence analysis to validate new outcome measures, biomarkers and therapeutic targets for FacioScapuloHumeral muscular dystrophy
- ReSOLVE FSHD International: Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- 1821-FSH-301: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD)
Acronym |
Resolve France Expansion |
PROGRESS FSHDÂ |
ReSOLVE FSHD International |
1821-FSH-301Â |
| Intervention | – | – | – | FSH-301 |
| Principal investigator |
Teresinha Evangelista | Teresinha Evangelista | Guillaume Bassez | Teresinha Evangelista |
| Sponsor | CHU of Nice | CHU of Nice | CHU of Nice | Fulcrum Therapeutics |
| Study status |
Active | In preparation | Active | Beginning soon |
| Recruitment status | Ongoing | Beginning soon | Completed | Beginning soon |
| Population | Adult | Adult | Adult | Adult |
| Â | + infos on clinicaltrials.gov | + infos on clinicaltrials.gov |
Contact : essais-adultes@institut-myologie.org
